Intervention measures for maintenance of clinical control in the remission stage of childhood asthma
ZHANG Xue, PAN Jia-Hua, ZHOU Hao-Quan
Department of Pediatrics, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
Abstract：Objective To explore the intervention measures to maintain clinical control in children with asthma in the remission stage when concomitant with acute upper respiratory infection (AURI). Methods A total of 100 asthmatic children who had achieved clinical control were randomly divided into observation group and control group. The two groups were both treated with a combination of inhaled corticosteroids and long-acting β2 receptor agonist (ICS/LABA) at the lowest dose every night. Conventional therapies were used for the two groups when suffering from AURI. In addition to conventional therapies, the observation group was given early short-term upgrade therapy, i.e., on the basis of maintenance therapy, the same amount of ICS/LABA complex preparation was inhaled every morning, which lasted for 7-10 days. Both groups were treated following asthma guidelines according to the severity of the disease at the time of acute attacks. The control rate of asthma, severity of acute attacks, changes in pulmonary function indices, and occurrence of adverse events were evaluated after 3, 6, 9, and 12 months of treatment. Results At each time point of follow-up, the rate of asthma control in the observation group was significantly higher than that in the control group (90% vs 80%; P < 0.05). The severity of acute attacks in the observation group was significantly lower than that in the control group at all follow-up time points (P < 0.05). Compared with the control group, the observation group had significantly improved pulmonary function indices of large and small airways (P < 0.05) and significantly reduced mean amount of inhaled glucocorticoids and impact on family life (P < 0.01). Conclusions Early short-term upgrade therapy for children with asthma in the remission stage when concomitant with AURI can prevent acute attacks of asthma, raise the rate of asthma control and improve pulmonary function.
ZHANG Xue,PAN Jia-Hua,ZHOU Hao-Quan. Intervention measures for maintenance of clinical control in the remission stage of childhood asthma[J]. CJCP, 2019, 21(6): 499-504.
Edlmayr J, Niespodziana K, Focke-Tejkl M, et al. Allergen-specific immunotherapy:towards combination vaccines for allergic and infectious diseases[J]. Curr Top Microbiol Immunol, 2011, 352:121-140.
[2]
Gidaris D, Urquhart D, Anthracopoulos MB. They said it was bronchiolitis; is it going to turn into asthma doctor?[J]. Respirology, 2014, 19(8):1158-1164.
Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children[J]. J Allergy Clin Immunol, 2017, 140(4):895-906.
[9]
Zomer-Kooijker K, Uiterwaal CS, Verschueren KJ, et al. Respiratory tract infections and asthma control in children[J]. Respir Med, 2014, 108(10):1446-1452.
[10]
Bønnelykke K, Vissing NH, Sevelsted A, et al. Association between respiratory infections in early life and later asthma is independent of virus type[J]. J Allergy Clin Immunol, 2015, 136(1):81-86.
[11]
Beigelman A, Bacharier LB. Early-life respiratory infections and asthma development:role in disease pathogenesis and potential targets for disease prevention[J]. Curr Opin Allergy Clin Immunol, 2016, 16(2):172-178.
[12]
Berry SM, Connor JT, Lewis RJ. The platform trial:an efficient strategy for evaluating multiple treatments[J]. JAMA, 2015, 313(16):1619-1620.
[13]
Hatziagorou E, Kouroukli E, Galogavrou M, et al. Efficacy and safety of the combination fluticasone propionate plus salmeterol in asthmatic preschoolers:an observational study[J]. J Asthma, 2018:1-8.
[14]
Cazeiro C, Silva C, Mayer S, et al. Inhaled corticosteroids and respiratory infections in children with asthma:a meta-analysis[J]. Pediatrics, 2017, 139(3). pii:e20163271.
[15]
Kim SR, Song JH, Ahn JH, et al. Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation[J]. Antiviral Res, 2018, 151:87-96.
[16]
O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma[J]. N Engl J Med, 2018, 378(20):1865-1876.
[17]
Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma[J]. Eur Respir J, 2018, 51(1). pii:1701688.
[18]
Yoshihara S, Fukuda H, Tamura M, et al. Efficacy and safety of salmeterol/fluticasone combination therapy in infants and preschool children with asthma insufficiently controlled by inhaled corticosteroids[J]. Drug Res (Stuttg), 2016, 66(7):371-376.
